Literature DB >> 19443627

A case for water in the treatment of polycystic kidney disease.

Vicente E Torres1, Lise Bankir, Jared J Grantham.   

Abstract

Autosomal dominant polycystic disease (ADPKD) is an inherited disorder characterized by the development within renal tubules of innumerable cysts that progressively expand to cause renal insufficiency. Tubule cell proliferation and transepithelial fluid secretion combine to enlarge renal cysts, and 3'-5'-cyclic adenosine monophosphate (cAMP) stimulates that growth. The antidiuretic hormone, arginine vasopressin (AVP), operates continuously in ADPKD patients to stimulate the formation of cAMP, thereby contributing to cyst and kidney enlargement and renal dysfunction. Studies in animal models of ADPKD provide convincing evidence that blocking the action of AVP dramatically ameliorates the disease process. In the current analysis, the authors reason that increasing the amount of solute-free water drunk evenly throughout the day in patients with ADPKD and normal renal function will decrease plasma AVP concentrations and mitigate the action of cAMP on the renal cysts. Potential pitfalls of increasing fluid intake in ADPKD patients are considered, and suggestions for how physicians may prudently implement this therapy are offered.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19443627     DOI: 10.2215/CJN.00790209

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  52 in total

1.  Water prescription in autosomal dominant polycystic kidney disease: a pilot study.

Authors:  Connie J Wang; Catherine Creed; Franz T Winklhofer; Jared J Grantham
Journal:  Clin J Am Soc Nephrol       Date:  2010-09-28       Impact factor: 8.237

Review 2.  Novel role of ouabain as a cystogenic factor in autosomal dominant polycystic kidney disease.

Authors:  Gustavo Blanco; Darren P Wallace
Journal:  Am J Physiol Renal Physiol       Date:  2013-06-12

Review 3.  Rationale for early treatment of polycystic kidney disease.

Authors:  Jared J Grantham
Journal:  Pediatr Nephrol       Date:  2014-07-15       Impact factor: 3.714

Review 4.  Vasopressin: a novel target for the prevention and retardation of kidney disease?

Authors:  Lise Bankir; Nadine Bouby; Eberhard Ritz
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

5.  Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial.

Authors:  Olivier Devuyst; Arlene B Chapman; Ron T Gansevoort; Eiji Higashihara; Ronald D Perrone; Vicente E Torres; Jaime D Blais; Wen Zhou; John Ouyang; Frank S Czerwiec
Journal:  J Am Soc Nephrol       Date:  2016-12-05       Impact factor: 10.121

6.  Novel treatments of autosomal dominant polycystic kidney disease.

Authors:  Rex L Mahnensmith
Journal:  Clin J Am Soc Nephrol       Date:  2014-04-10       Impact factor: 8.237

Review 7.  Strategies targeting cAMP signaling in the treatment of polycystic kidney disease.

Authors:  Vicente E Torres; Peter C Harris
Journal:  J Am Soc Nephrol       Date:  2013-12-12       Impact factor: 10.121

8.  Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells.

Authors:  Tamio Yamaguchi; Gail A Reif; James P Calvet; Darren P Wallace
Journal:  Am J Physiol Renal Physiol       Date:  2010-09-01

Review 9.  Predictors of autosomal dominant polycystic kidney disease progression.

Authors:  Robert W Schrier; Godela Brosnahan; Melissa A Cadnapaphornchai; Michel Chonchol; Keith Friend; Berenice Gitomer; Sandro Rossetti
Journal:  J Am Soc Nephrol       Date:  2014-06-12       Impact factor: 10.121

10.  Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Marie E Edwards; Fouad T Chebib; Maria V Irazabal; Troy G Ofstie; Lisa A Bungum; Andrew J Metzger; Sarah R Senum; Marie C Hogan; Ziad M El-Zoghby; Timothy L Kline; Peter C Harris; Frank S Czerwiec; Vicente E Torres
Journal:  Clin J Am Soc Nephrol       Date:  2018-07-19       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.